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1LETTER TO THE EDITOR
harmacokinetics of Oral Mycophenolate Mofetil
n Dog: Bioavailability Studies and the Impact
f Antibiotic Therapy
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iAn improved understanding of the pharmacokinetics
f mycophenolic acid (MPA), the active metabolite of
he immunosuppressant mycophenolate mofetil (MMF),
s needed because of the increasing use of MMF in
atients undergoing solid-organ transplantation [1] or
ematopoietic cell transplantation (HCT) [2-4]. Plasma
oncentrations of MPA have been correlated with vari-
us clinical outcomes in solid-organ transplant recipients
1]. However, only recently have pharmacodynamic as-
ociations been described in patients undergoing HCT,
peciﬁcally the correlation of increased MPA concentra-
ions at steady state [3] and the unbound MPA area
nder the concentration-time curve (AUC) [4], with
igher degrees of donor T cell chimerism [3] and lower
ncidences of graft rejection [3,4], respectively.
Recent studies in a well-established preclinical ca-
ine model of HCT have identiﬁed effective immu-
osuppressive drug combinations that include MMF
or the prevention of acute allograft rejection and
raft-versus-host disease [5,6]. In these studies, MMF
as administered subcutaneously at a dose of 10
g/kg twice daily. We sought to determine in a
ealthy 25-month-old male beagle the bioavailability
nd interdose variability of oral MMF to develop an
nderstanding of drug dosing required for substitut-
ng oral for subcutaneous MMF. Because enterohe-
atic circulation mediated through gram-negative
ntestinal bacteria plays a major role in MPA pharma-
okinetics [7], we also addressed the question of
hether gut decontamination with nonabsorbable an-
ibiotics affects the enterohepatic circulation in the
og, which could have potential clinical implications
or canine marrow graft recipients. MPA bioavailabil-
ty was investigated on 3 occasions, each separated
rom the others by 1 month, after single doses (ie, 10,
5, and 20 mg/kg) of oral MMF (CellCept Oral Sus-
ension, Roche Laboratories. Nutley, NJ; 200 mg/
L) and compared with that of a single subcutaneous
ose of 10 mg/kg MMF (CellCept Intravenous, Roche
aboratories; 25 mg/mL); each oral dose was sepa-
ated from the baseline subcutaneous dose by a 3-day
est period. The effect of nonabsorbable antibiotics on
ral MMF pharmacokinetics was evaluated on 4 oc- i
352asions, 1 month apart. At baseline, the dog was given
single dose of 15 mg/kg oral MMF, followed by 3
ays of rest, and then received a nonabsorbable anti-
iotic mixture consisting of a 1:1 ratio of neomycin
ulfate (Biosol, The Upjohn Company, Kalamazoo,
I) and polymyxin B sulfate (Polymyxin B, Bedford
aboratories, Bedford, OH), each administered at a
ose of 1 g orally per total body weight, 3 times daily,
0 days before and concomitant with another dose of
5 mg/kg oral MMF. Plasma samples were obtained
efore and 1, 2, 4, 6, 8, 10, and 12 hours, respectively,
fter each MMF dose. Pharmacokinetic parameters
ere quantiﬁed and analyzed as previously reported
3]. The interdose variability was assessed by compar-
ng the variances of the various measurements of the
harmacokinetic parameters using the F test; P 0.05
as considered statistically signiﬁcant.
The pharmacokinetic data are presented in Table 1.
ioavailabilities were 54%, 65%, and 87% after 10,
5, and 20 mg/kg oral MMF, respectively. The plasma
oncentration-time proﬁle after oral MMF was char-
cterized by secondary maxima induced by the entero-
epatic circulation within 4-12 hours of dosing. There
ere statistically signiﬁcant differences in interdose
ariabilities in the MPA clearance and total MPA
aximum plasma concentration (Cmax; P  .02 and
006, respectively), but not in the MPA-free fraction
nd AUC from 0 to 12 hours (AUC0-12h; P  .16 and
07, respectively) after oral versus subcutaneous MMF
dministrations (Table 1). Administration of preced-
ng and concomitant nonabsorbable antibiotics with a
ingle oral MMF dose did not appear to reduce the
PA-free fraction, AUC0-12h, clearance, and Cmax
hen compared with oral MMF given without anti-
iotics (Table 1); however, the average of the second-
ry MPA peaks to the AUC0-12h was reduced by
7.2% (P  .64). The interdose variabilities in the
PA-free fraction, AUC0-12h, clearance, and Cmax
ere not statistically signiﬁcantly different after oral
MF given with or without nonabsorbable antibiotics
P  .30, .39, .42, and .21, respectively; Table 1); high
nterdose variabilities, although not statistically signif-
cantly different, were seen in the amplitude of the
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Letter to the Editor 1353econdary MPA peaks to the AUC0-12h after oral
MF given with preceding and concomitant nonab-
orbable antibiotics compared with oral MMF given
lone (P  .06; Table 1).
Our data suggested that interdose variability after
ral MMF administration occurred even under well-
ontrolled environmental conditions. Using oral MMF
fter HCT would expose the dogs to unwarranted risks
ue to excessive or suboptimal MPA concentrations that
ould lessen the potency of immunosuppression neces-
ary for successful HCT; therefore, oral MMF would
ot be a good substitute for subcutaneous MMF in the
reclinical canine HCT model, where MPA plasma lev-
ls are not routinely monitored and adequate levels of
mmunosuppression are essential for preclinical valida-
ion of the HCT protocols. Our ﬁndings support the
eed for rational individual therapeutic monitoring of
PA levels in patients undergoing HCT, where the use
f pretransplantation test doses did not accurately pre-
ict total or unbound MPA AUC after HCT [4].
On average, the effects of nonabsorbable antibiot-
cs on MPA pharmacokinetics were not signiﬁcant
elative to the interdose variability seen. It has been
ecently reported that patients after HCT had lower
lasma MPA levels and a shorter MPA half-life after
ral MMF administration compared with healthy vol-
nteers or solid-organ transplant recipients [2]. That
ight be attributed to the decreased bacterial ﬂora in
he gastrointestinal tract from broad-spectrum pro-
hylactic antibiotic use. Further, it has been suggested
hat a signiﬁcant fraction of the interdose variability in
PA pharmacokinetics was caused by day-to-day
uctuations in the contribution of MPA enterohepatic
irculation to the MPA AUC [8]. In addition to gen-
rating a hypothesis, our study provided preliminary
ata regarding the effects of nonabsorbable antibiotics
n the enterohepatic circulation of MPA, which could
able 1. Pharmacokinetic Parameters in a Healthy Dog Following Adm
MMF Route/Dose
(mg/kg) N
Unbound
MPA (%)
MPA AUC
(mg*hr/m
C
10 3 2.09  0.4* 20.89  2
O
10 1 1.93 13.17
15 5 1.95  0.23* 20.77  1
20 1 1.82 33.7
O  nAb
15 4 1.75  0.16* 21.94  1
bbreviations: AUC0-12h  area under the concentration-time curv
mycophenolate mofetil; MPA  mycophenolic acid; N  numb
Average  standard deviation.e further investigated in patients after HCT.CKNOWLEDGMENTS
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